EUCTR2014-000383-18-IT进行中（未招募）1 期
ational Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy - LAL1913
G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto0 个研究点目标入组 204 人开始时间: 2014年3月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 204
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed written informed consent according to ICH/EU/GCP and national local laws.
- •2. Age 18-65 years.
- •3. A diagnosis of untreated Ph- ALL or LL is required, either de novo or secondary to chemo-radiotherapy for other cancer. Pretreatment with low-dose corticosteroids in patients presenting with hyperleukocytosis is allowed. All diagnostic procedures need to be performed on freshly obtained bone marrow (BM) and peripheral blood (PB) samples. The diagnosis must be one of: de novo ALL, secondary ALL, B-/T-cell LL
- •4. Full cytological, cytochemical, cytogenetic and immunobiological disease characterization according to EGIL and WHO classifications. Bone marrow and peripheral blood sampling (ALL) or biopsy specimen (LL) are required for MRD study. Detailed indications on patient registration, storage of representative diagnostic material and diagnostic work-up, including the forwarding of samples for MRD study are given in Appendix B.
- •5. Bone marrow and peripheral blood sampling (ALL) or biopsy specimen (LL) for MRD study.
- •6. ECOG performance status 0-2, unless a performance of 3 is unequivocally caused by the disease itself and not by preexisting comorbidity, and is considered and/or documented to be reversible following the application of antileukemic therapy and appropriate supportive measures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 204
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Diagnosis of Burkitt’s leukemia or lymphoma.
- •2. Down’s syndrome
- •3. Pre-existing, uncontrolled pathology such as heart failure (congestive/ischemic, acute myocardial infarction within the past 3 months, untreatable arrhythmias, NYHA classes III and IV), severe liver disease with serum bilirubin >3 mg/dL and/or ALT >3 x upper normal limit (unless attributable to ALL), kidney function impairment with serum creatinine >2 mg/dL (unless attributable to ALL), and severe neuropsychiatric disorder that impairs the patient’s ability to understand and sign the informed consent, or to cope with the intended treatment plan. N.B. For altered liver and kidney function tests, eligibility criteria can be reassessed at 24-96 hours, following the institution of adequate supportive measures.
- •4. Pre-existing HIV positive serology (i.e. already known before enrolment). If HIV positivity is detected after enrolment, the patient is sent off study.
- •5. A history of cancer that is not in a remission phase following surgery and/or radiotherapy and/or chemotherapy, with life expectancy <1 year.
- •6. Pregnancy declared by the patient herself, unless a decision is taken with the patient to induce a therapeutic abortion in order to carry on with ALL therapy. A pregnancy test is performed at diagnosis but does not preclude the enrolment into study. Fertile patients will be advised to adopt contraceptive methods while on treatment.
研究者
相似试验
招募中
3 期
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and Blinatumomab, a specific monoclonal antibody, in adult patients, compared to the administration of chemotherapy and Imatinib. ALL28202023-508968-30-00Fondazione Gimema Franco Mandelli Onlus236
进行中（未招募）
1 期
ong-term follow-up of adult patients previously enrolled in Study 00103311 with a type of acute lymphoblastic leukemia that did not respond to previous therapy or that relapsed after initially successful previous therapyAdult patients with relapsed and/or refractory B-precursor acute lymphoblastic leukaemialastic leukaemiaMedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2019-001575-37-ITAMGEN INC.75
进行中（未招募）
1 期
ong-term follow-up of adult patients previously enrolled in Study 00103311 with a type of acute lymphoblastic leukemia that did not respond to previous therapy or that relapsed after initially successful previous therapyAdult patients with relapsed and/or refractory B-precursor acute lymphoblastic leukaemialastic leukaemiaMedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2019-001575-37-DEAmgen Inc.108
撤回
不适用
Rolandic Care Programseizures100399111001256210001474epilepsyNL-OMON45331Epilepsiecentrum Kempenhaeghe125
已完成
不适用
ifestyle program in treatment of Pompe disease. Combining exercise training and dietary intervention.Pompe's diseaseGlycogen storage disease type II (GSD II)Acid maltase deficiency.1000054610028302NL-OMON50978Erasmus MC, Universitair Medisch Centrum Rotterdam43